To understand the mechanism of the clinical efficacy of olanzapine and fluoxetine combination therapy for treatment-resistant depression (TRD
Although many antidepressants demonstrate some efficacy in the treatment of major depression, a common and debilitating disease affecting about 10% of the population, 10-30% of patients fail to respond to a single antidepressant treatment and as many as 50-75% of patients respond only partially to antidepressant therapy (Amsterdam and Hornig-Rohan 1996; Kessler et al. 1994; Nierenberg and Amsterdam 1990; Roose et al. 1986 ). Various pharmacologic options, such as titration to higher doses of the initial agent, a switch to an alternative agent, or augmentation (combination) therapy have been studied in the effort to achieve better therapy for treatment-resistant depressive disorder (TRD). Previous experimental research has been mostly focused on such augmentation strategies as the addition of lithium to a tricyclic antidepressant (TCA), to which a large proportion of patients still fail to respond (Nelson 1998; Thase and Rush 1995) . Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, although having long been proved effective in the treatment of minor and major depression, are less well studied in an augmentation context. In a recent 8-week, double-blind clinical trial, olanzapine, a novel "atypical" antipsychotic agent effective against both positive and negative symptoms of schizophrenia (Beasley et al. 1996) as well as depressive symptoms in psychotic patients (Tollefson et al. 1998) , was combined with fluoxetine therapy. The combination therapy demonstrated a significantly greater improvement on the MADRS and CGI-S, and a numeric advantage on the HAMD-21 in patients with TRD without psychotic features, than either olanzapine or fluoxetine monotherapy (Tohen et al. 1999) . Moreover, this advantage was evident after the first week of treatment (Tohen et al. 1999) . Thus, the combination of olanzapine and fluoxetine in this pilot study produced a rapid and dramatic result in heretofore unresponsive patients.
Olanzapine has a broad binding profile and is an antagonist at a number of neuronal receptors including dopamine (DA) D 1 -D 5 , serotonin (5-HT) 2A, B, C , ␣ 1 -adrenergic, histamine H 1 and muscarinic M 1-5 receptor subtypes both in vitro and in vivo (Bymaster et al. 1996; Schotte et al. 1996; Zhang and Bymaster 1999) . In animal experiments, olanzapine robustly increased DA and norepinephrine (NE) extracellular levels ([DA] ex , [NE] ex ) in rat medial prefrontal cortex (mPFC) (Li et al. 1998 ), a brain region that is crucial for cognition, affect and social behavior (Berman and Weinberger 1990; GoldmanRakic 1996) . The selective serotonin reuptake inhibitor (SSRI) fluoxetine, in addition to increasing 5-HT extracellular levels Fuller 1992, 1997) and PFC (Gobert et al. 1997) .
Disturbances in NE, DA, as well as 5-HT neurotransmitter system have been suggested to be involved in the pathogenesis of mood disorders including depression (Maes and Meltzer 1995; Schatzberg and Schildkraut 1995; Willner 1995) . We hypothesized that the combination of olanzapine and fluoxetine would produce significant changes in extracellular levels of monoamines that may underlie the robust clinical efficacy of the combination therapy. Therefore, we studied the effects of olanzapine and fluoxetine alone and in combination on ex , [DA] ex and [NE] ex in rat PFC utilizing a microdialysis technique. To investigate a potential pharmacokinetic interaction, the plasma and brain levels of olanzapine and fluoxetine when administered alone or in combination were also determined in rat. In addition, to explore the possible receptor mechanisms mediating the neurochemical changes, we also examined the effects of other antipsychotics including clozapine, risperidone, haloperidol and the selective 5-HT 2A antagonist MDL 100907 in the same experimental paradigm. Furthermore, another selective SSRI, sertraline (Heym and Koe 1988; Koe et al. 1983) , was also investigated for its effect on 
METHODS

Animal Surgery
Male Sprague-Dawley rats with body weight 260-300 g (Harlan, Sprague-Dawley, Indianapolis, IN) were used in the microdialysis studies. Rats were anesthetized with chloral hydrate/pentobarbital (170 mg/kg and 36 mg/kg in 30% propylene glycol and 14% ethanol, respectively) on operation day to allow the implantation of dialysis probes. Loop style microdialysis probes were constructed and implanted in the rat prefrontal cortex two days prior to use according to a previously published method (Perry and Fuller 1992) . Coordinates for the PFC were: A (anterior to bregma) 3.2 mm, L (lateral from the midsagittal suture) 0.8 mm, and V (ventral from the dura surface) 4 mm (Paxinos and Watson 1986) . At the end of the experiments, the probe positions were histologically verified. Rats with improper probe location or monoamine baseline values were not included in the statistical analysis.
Microdialysis
On the day of the experiment, an artificial cerebrospinal fluid (pH 7.4; composed of 150 mM NaCl, 3 mM KCl, 1.7 mM CaCl 2 , and 0.9 mM MgCl 2 ) was delivered to the probe at a flow rate of 2.0 l/min. Dialysate samples (30 l) were collected every 15 minutes up to 4 hours and [5-HT] ex , [DA] ex and [NE] ex were assayed on-line using HPLC with electrochemical detection according to a previously published method (Li et al. 1998 ). The sensitivity of detection was about 3 fmol per 30 l sample. The effects of drugs were determined after achieving a stable baseline for at least 3 samples.
Drug Treatment
All drugs were administered in a volume of 1 ml/kg through an implanted subcutaneous (s.c.) tube to avoid handling the rats during the experiments. Antipsychotics were dissolved in 0.01N HCl, further acidified and sonicated if necessary. The pH of solutions was adjusted to 4-7. SSRIs were dissolved in distilled water. Dosage of antipsychotic agents were chosen according to each drug's in vivo potencies of blocking DA D 2 or 5-HT 2A receptors reported in previous publications (Li et al. 1998; Zhang and Bymaster 1999) . The SSRIs were given in doses that increased [5-HT] ex in previous publications Fuller 1992, 1997; Sprouse et al. 1996) . In the combination studies, antipsychotic agents were administered 30 minutes prior to SSRI injection to decrease potential pharmacokinetic interactions. Each drug or drug combination was given to 5-6 rats which received either a single drug or single drug combination.
Plasma and Brain Levels of Drugs
For determination of plasma and brain levels of olanzapine, fluoxetine, and norfluoxetine, male Sprague-Dawley ( n ϭ 3 per group) weighing about 250-300 g were administered 3 mg/kg (s.c.) olanzapine and 10 mg/kg (s.c.) fluoxetine 2 and 1.5 hours prior to euthanasia with carbon dioxide, respectively. The combination group received olanzapine and fluoxetine 2 and 1.5 hours prior to sample collection, respectively. Following anesthesia with carbon dioxide, blood samples were collected by cardiac puncture in heparinized tubes, and plasma was collected by centrifugation. Subsequently, the brain was perfused with normal saline, excised and weighed. Four milliliters of distilled water/g brain was added and the tissue was homogenized. Brain homogenates and plasma samples were then frozen in dry ice and stored at approximately Ϫ 70 Њ C until analysis.
Plasma and brain samples were analyzed for fluoxetine and norfluoxetine concentrations using validated HPLC/MS/MS assays. Plasma samples were prepared for quantitation by adding potassium phosphate buffer (pH 6) and internal standard to 0.5 ml of plasma and extracting on an Isolute HCX solid phase extraction column. The samples were eluted with 2% ammonium hydroxide in methylene chloride/methanol, evaporated, and reconstituted in mobile phase (methanol/0.05% trifluoroacetic acid, 80/20). Brain samples were extracted in 5 ml of 0.3% butanol in hexane following the addition of 1% diethylamine, 1N NaOH and internal standard to 0.5 ml of brain homogenate. The organic layer was evaporated and reconstituted in mobile phase. The plasma and brain extracts were chomatographed by HPLC on a Waters Nova-Pak CN HP column and quantitated by MS/MS with atmospheric pressure chemical ionization.
Olanzapine plasma and brain concentrations were determined using validated HPLC/electrochemical assays. Potassium phosphate buffer (pH 6) and internal standard were added to 1.0 ml of plasma. The plasma samples were loaded onto Varian Certify solid phase extraction columns and eluted with 0.5% ammonium hydroxide in ethyl acetate. The eluate was evaporated and reconstituted in mobile phase (75 mM phosphate buffer/methanol/acetonitrile, 45/35/20). Brain extracts were prepared by adding sodium carbonate and internal standard to 0.5 ml of rat brain homogenate and extracting with 5 ml of 15% dichloromethane in cyclohexane. The organic layer was evaporated and reconstituted in mobile phase. The plasma and brain extracts were chomatographed by HPLC on a YMC Basic column and quantitated by electrochemical detection.
Data Analysis
All microdialysis data were calculated as percent change from dialysate basal concentrations with 100% defined as the average of the final three drug preinjection values. The overall effects of each drug treatment on monoamine level changes over the 4 hour experimental period were analyzed by calculating the average percentage of the baseline. In addition, changes at the 4 hour time point were chosen to study the end result of each drug treatment. Significant differences of percentage change at each time point compared with baseline values were determined by Student's t-test for paired samples. Significant differences among the treatment groups were determined by using a one-way analysis of variance (ANOVA) followed by Student's t-test. The minimal level for statistical significance was set at p Ͻ .05.
RESULTS
Baseline Values of Extracellular 5-HT, DA and NE in PFC
The basal 
Effects of Olanzapine and Fluoxetine Alone and In Combination on Extracellular Monoamine Levels in PFC
Olanzapine (3 mg/kg, s.c.) alone did not significantly affect [5-HT] ex , whereas fluoxetine (10 mg/kg, s.c.) elevated [5-HT] ex up to a peak value of 388 Ϯ 57% of the baseline ( p Ͻ .05) with an average of 368 Ϯ 54% of the baseline over the 4 hour period ( p Ͻ .05) ( Figure 1A , Table 1A). At 4 hours after fluoxetine treatment, the increase of ex was sustained at 382 Ϯ 66% of the baseline ( p Ͻ .05) ( Figure 1A , Table 1B ). In the olanzapine plus fluoxetine treatment group, [5-HT] ex was increased up to a peak value of 338 Ϯ 33% at the 4 hour time point, and the average over the experimental period was 278 Ϯ 15% of the baseline (both p Ͻ .05) ( Figure 1A , Tables 1A  and 1B ). The increase of [5-HT] ex in the combination treatment was not significantly different from the increase caused by fluoxetine treatment alone.
Olanzapine and fluoxetine alone both significantly increased [DA] ex up to peak values of 246 Ϯ 38% and 175 Ϯ 16% with averages of 166 Ϯ 17% and 150 Ϯ 7% of the baseline (all p Ͻ .05), respectively, over the 4 hour period ( Figure 1B , Table 1A ). At 4 hours after drug treatment, [DA] ex returned to baseline in the olanzapine-treated group, but remained significantly elevated at 134 Ϯ 4% of the baseline ( p Ͻ .05) in the fluoxetinetreated group ( Figure 1B , Table 1B ). Compared to either olanzapine or fluoxetine alone, the olanzapine plus fluoxetine treatment increased [DA] ex more robustly and persistently up to peak values of 361 Ϯ 28% with an average of 332 Ϯ 30% of the baseline over the treatment period (both p Ͻ .05) ( Figure 1B , Table 1A ). This increase of [DA] ex was sustained at 315 Ϯ 30% of the baseline (p Ͻ .05) at the 4 hour time point by the combination treatment ( Figure 1B , Table 1B ).
Olanzapine and fluoxetine alone both significantly increased [NE] ex up to peak values of 187 Ϯ 16% and 209 Ϯ 26% with averages of 133 Ϯ 9% and 189 Ϯ 19% of the baseline over the 4 hour period (all p Ͻ .05), respectively ( Figure 1C , Table 1A ). At 4 hours after drug treatment, [NE] ex returned to baseline in the olanzapine-treated group, but remained elevated at 180Ϯ27% of the baseline (p Ͻ .05) in the fluoxetine-treated group ( Figure 1C , Table 1B). Compared to either olanzapine or fluoxetine alone, the olanzapine plus fluoxetine treatment increased [NE] ex more robustly and persistently up to a peak value of 272 Ϯ 16% with an average of 260 Ϯ 19% of the baseline over the treatment period (both p Ͻ .05) ( Figure 1C , Table 1A ). This increase of [NE] ex was sustained at 242 Ϯ 28% of the baseline (p Ͻ .05) at the 4 hour time point by the combination treatment ( Figure 1C , Table 1B ).
Effects of Clozapine Alone and in Combination with Fluoxetine on Extracellular Monoamine Levels in PFC
Clozapine (3 mg/kg, s.c.) alone did not significantly affect [5-HT] ex over the 4 hour period ( Figure 2A , Table  1A ). In the clozapine plus fluoxetine treatment group, [5-HT] ex was elevated up to a peak value of 395 Ϯ 73% with an average of 364 Ϯ 51% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 2A , Table 1A) , and the level remained at 354 Ϯ 36% of the baseline at the 4 hour time point (p Ͻ .05) ( Figure 2A , Table 1B ). The increase of ex in the combination treatment was not significantly different from fluoxetine treatment alone.
Clozapine alone significantly increased [DA] ex up to a peak value of 236 Ϯ 36% with an average of 194 Ϯ 29% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 2B , Table 1A ). At 4 hours after clozapine treatment, [DA] ex returned to baseline ( Figure 2B , Table 1B ). The clozapine plus fluoxetine treatment increased [DA] ex up to a peak value of 36 1Ϯ 36% with an average of 228 Ϯ 12% of the baseline over the treatment period, which was significantly greater than either drug alone (both p Ͻ .05) ( Figure 2B , Table 1A ). This increase was sustained at 134 Ϯ 6% of the baseline (p Ͻ .05) at the 4 hour time point ( Figure 2B , Table 1B) .
Clozapine alone significantly increased [NE] ex up to a peak value of 218 Ϯ 30% with an average of 154 Ϯ 20% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 2C , Table 1A ). At 4 hours after clozapine treatment, [NE] ex returned to baseline ( Figure 2C , Table 1B ). In the clozapine plus fluoxetine treatment group, [NE] ex increased up to a peak value of 210 Ϯ 9% with an aver- age of 146 Ϯ 17% of the baseline (both p Ͻ .05) ( Figure  2C , Table 1A) , and the increase of [NE] ex returned to baseline at the 4 hour time point ( Figure 2C , Table 1B ). The increase of [NE] ex in the clozapine plus fluoxetine treatment group was not significantly different from either clozapine or fluoxetine treatment alone.
Effects of Risperidone Alone and in Combination with Fluoxetine on Extracellular Monoamine Levels in PFC
Risperidone (1 mg/kg, s.c.) alone did not significantly affect [5-HT] ex over the 4 hour period ( Figure   3A , Table 1A ). In the risperidone plus fluoxetine treatment group, [5-HT] ex was elevated up to a peak value of 474 Ϯ 72% at the 4 hour time point with an average of 406 Ϯ 73% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 3A , Tables 1A and 1B) . The increase of [5-HT] ex in the combination treatment was not significantly different from fluoxetine treatment alone.
Risperidone alone significantly increased [DA] ex up to a peak value of 187 Ϯ 15% with an average of 134 Ϯ 8% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 3B , Table 1A ). At 4 hours after risperidone treatment, [DA] ex returned to the baseline (Fig- ure 3B, Table 1B ). The risperidone plus fluoxetine treatment increased [DA] ex up to a peak value of 305 Ϯ 43% with an average of 255 Ϯ 44% of the baseline over the treatment period (both p Ͻ .05) ( Figure 3B , Table 1A ). The average increase of [DA] ex produced by the combination was significantly different from either risperidone or fluoxetine treatment alone (p Ͻ .05). The level of [DA] ex was sustained at 210 Ϯ 26% of the baseline (p Ͻ .05) at the 4 hour time point ( Figure  3B , Table 1B ). Risperidone alone significantly increased [NE] ex up to a peak value of 243 Ϯ 22% with an average of 159 Ϯ 10% of the baseline over the 4 hour period (both p Ͻ .05) ( Figure 3C , Table 1A ). At 4 hours after drug treatment, [NE] ex returned to the baseline ( Figure 3C , Table 1B ). In the risperidone plus fluoxetine treatment group, [NE] ex increased up to a peak value of 227 Ϯ 46% with an average of 200 Ϯ 39% of the baseline over the treatment period (both p Ͻ .05) ( Figure 3C , Table 1A ). The level of [NE] ex was 166 Ϯ 33% at the 4 hour time point, which was not significantly different from the baseline ( Figure  3C , Table 1B ). The increase of [NE] ex in the risperidone plus fluoxetine treatment group was not significantly different from either risperidone or fluoxetine treatment alone. Figures 5A, 5B , and 5C, Tables 1A and 1B). The monoamine extracellular levels after administration of MDL 100907 plus fluoxetine were lower than those produced by fluoxetine treatment alone.
Effects of Haloperidol Alone and in Combination with Fluoxetine on Extracellular Monoamine Levels in PFC
Effects of Sertraline Alone and in Combination with Olanzapine on Extracellular Monoamine Levels in PFC
Sertraline (10 mg/kg, s.c.) alone increased [5-HT] ex up to a peak value of 462 Ϯ 66% (p Ͻ .05) with an average of 432 Ϯ 57% of the baseline over the 4 hour period (p Ͻ .05) ( Figure 6A , Table 1A ). At 4 hours after sertraline treatment, the level of [5-HT] ex was sustained at 455 Ϯ 62% of the baseline (p Ͻ .05) ( Figure 6A , Table 1B ). In the olanzapine plus sertraline treatment group, [5-HT] ex increased up to a peak value of 344 Ϯ 53% of the baseline at 4 hour time point with an average of 311 Ϯ 43% of the baseline over the 4 hour period (both p Ͻ .05) (Fig. 6A, Tables 1A and 1B) . The increase of [5-HT] ex in the combination treatment was not significantly different from sertraline treatment alone, although it was consistently lower in magnitude.
Sertraline alone only transiently increased [DA] ex up to a peak value of 136 Ϯ 13% of the baseline (p Ͻ .05) with an average not significantly different from the baseline ( Figure 6B , Table 1A ). At 4 hours after drug treatment, [DA] ex returned to baseline ( Figure 6B , Table  1B ). The olanzapine plus sertraline treatment elevated [DA] ex to a peak value of 369 Ϯ 45% with an average of 270 Ϯ 16% over the 4 hour period. The [DA] ex level remained at 199 Ϯ 22% of the baseline at the 4 hour time point (all p Ͻ .05). The increase of [DA] ex was significantly higher than those in either the olanzapine or sertraline treatment alone (both p Ͻ .05).
Sertraline alone only transiently increased [NE] ex up to a peak value of 124 Ϯ 7% of the baseline (p Ͻ .05) with an average not significantly different from the baseline ( Figure 6C , Table 1A ). At 4 hours after sertraline treatment, [NE] ex returned to the baseline ( Figure  6C , Table 1B ). The olanzapine plus sertraline treatment elevated [NE] ex to a peak value of 198 Ϯ 12% with an average of 123 Ϯ 7% of the baseline (both p Ͻ .05). The increase of [NE] ex returned to baseline at the 4 hour time point. These changes of [NE] ex were not significantly different from either olanzapine or sertraline alone treatment groups.
Pharmacokinetic Interaction
At 2 hour after initial drug treatment, brain levels of olanzapine were 1008 Ϯ 103 ng/gm in the olanzapinetreated rats and 1065 Ϯ 90 ng/gm in the olanzapine plus fluoxetine-treated rats (Table 2) gm in the fluoxetine-treated rats and 9390 Ϯ 607 ng/gm in the olanzapine plus fluoxetine-treated rats. The brain levels of the active fluoxetine metabolite norfluoxetine were 1823 Ϯ 62 ng/gm in the fluoxetine-treated rats and 1318 Ϯ 103 ng/gm in the olanzapine plus fluoxetine-treated rats. Thus, brain levels of olanzapine in the olanzapine plus fluoxetine-treated rats were not significantly different from the olanzapine alone-treated group. In addition, the sum of fluoxetine and norfluoxetine concentrations in olanzapine plus fluoxetinetreated rats was not significantly different from that of the fluoxetine alone-treated group. The plasma levels of olanzapine, fluoxetine, and norfluoxetine from the combination treatment were not significantly different from treatment of either drug alone.
DISCUSSION
In our present study, we investigated the effects of systemic administration of a number of antipsychotic agents and two SSRIs alone and the combination of an antipsychotic agent plus SSRI on extracelluar levels of monoamines in rat prefrontal cortex. The doses of the antipsychotics and SSRIs were carefully chosen based on previously published studies. Olanzapine and clozapine doses (3 mg/kg, sc) were chosen to produce nearly equal increases of [DA] ex and [NE] ex in PFC, but were not peak doses in order to avoid potential ceiling effects (Li et al. 1998) . The dose of haloperidol (1 mg/kg, s.c.), MDL 100907 (1 mg/kg, s.c.), and risperidone (1 mg/kg, s.c.) were chosen based on previous publications (Hertel et al. 1996; Kuroki et al. 1999; Li et al. 1998; Schmidt and Fadayel 1995; Volonte et al. 1997) . The dose of fluoxetine (10 mg/kg, s.c.) has been previously used in our laboratory and produced the maximal increase in [5-HT] ex *Fluoxetine was given 0.5 hour after olanzapine or vehicle and 1.5 hour prior to measurement. Drug levels were measured in groups of three rats as described in Methods. Fuller 1992, 1997) . The dose of sertraline (10 mg/kg, s.c.) was chosen from published studies and is an effective dose for producing increases in [5-HT] ex (Sprouse et al. 1996) .
Consistent with previous findings (Hertel et al. 1996; Kuroki et al. 1999; Li et al. 1998; Volonte et al. 1997) , atypical antipsychotic agents including olanzapine, clozapine, and risperidone alone increased both [DA] ex and [NE] ex to varying degrees in rat cortical areas. Olanzapine, clozapine, and risperidone did not show appreciable changes on [5-HT] ex in PFC although risperidone was reported to increase [5-HT] ex in the rat medial PFC (Hertel et al. 1997; Ichikawa et al. 1998 ). Haloperidol, a typical antipsychotic with mainly D 2 /D 3 /D 4 antagonistic properties (Bymaster et al. 1997) and MDL 100907, a selective 5-HT 2A antagonist (Sorensen et al. 1993 ) did not significantly change any of these monoamine levels.
Although the present data on haloperidol, in general, agree with several previous studies, one study reported increases of both [DA] ex and [NE] ex to about 180% of the baseline induced by a dose of 800 nmol/kg (equivalent to 0.3 mg/kg, s.c.) of haloperidol (Westerink et al. 1998 ). However, several other studies reported no changes on either [DA] ex or [NE] ex induced by haloperidol (Kuroki et al. 1999; Li et al. 1998; Volonte et al. 1997) . One study also reported an increase of [DA] ex up to approximately 300% of the baseline by 1 mg/kg of MDL 100907 (Schmidt and Fadayel 1995) . The reason for these differences are unclear, but factors such as dissimilarities in the brain region of interest, drug dosage, types of dialysis probe, as well as "arousal" or "stress" produced by animal handling may contribute to the disparities in results. In the present study, drugs were administered remotely via a previously implanted s.c. cannula to avoid alteration of monoamine levels due to stress from handling. Overall, our results are in agreement with the majority of previous studies.
The two SSRIs fluoxetine and sertraline robustly increased [5-HT] ex in PFC, consistent with a number of previous studies on brain regions such as striatum and hypothalamus (Dreshfield et al. 1996; Perry and Fuller 1992; Sprouse et al. 1996) . However, while fluoxetine treatment resulted in a sustained elevation of [NE] ex and [DA] ex in PFC, consistent with previous reports in hypothalamus (Perry and Fuller 1997) (Thomas et al. 1998) .
The combination of olanzapine and fluoxetine produced robust and remarkably sustained increases of [DA] The olanzapine and fluoxetine combination treatment produced similar marked increases of [DA] ex , [NE] ex at the 2 hour time point (equivalent to 2 hours after olanzapine and 1.5 hours after fluoxetine administration) compared to those of the 4 hour time point. Our pharmacokinetic data showed that at 2 hours after olanzapine and 1.5 hours after fluoxetine drug administration, neither olanzapine, fluoxetine, nor the active fluoxetine metabolite norfluoxetine levels in brain were significantly higher in the combination treatment group than either drug alone treatment. Although the brain level of fluoxetine plus its active metabolite norfluoxetine was increased by 7% in the combined treatment with olanzapine and fluoxetine, this small increase is unlikely to explain the robust increases of [DA] ex and [NE] ex . Therefore, the robust increases in NE and DA that we observed in the combination treatment are more likely due to neurochemical mechanisms than a pharmacokinetic phenomenon.
Although we do not know the exact mechanism of the unique robust and persistent increase of [DA] ex and [NE] ex observed in the olanzapine plus fluoxetine combination treatment, several postulations are attempted here. Fluoxetine, olanzapine, and risperidone have relatively low affinity for 5-HT 1A receptors indicating that increases in catecholamines are probably not mediated by interaction with that receptor (Bymaster et al. 1996; Wong et al. 1995) . Since haloperidol, the typical antipsychotic with mainly D 2 /D 3 /D 4 antagonistic properties, or the selective 5-HT 2A antagonist MDL 100907 did not enhance any of fluoxetine's effect on monoamine release, the augmentation is likely not mediated by D 2 or 5-HT 2A receptors alone.
Atypical antipsychotics such as olanzapine, clozapine, and risperidone are similar in that they are multireceptorial agents and have relatively high affinities for a number of receptor subtypes, yet their respective re-ceptor binding profiles are somewhat different (Bymaster et al. 1996) . For example, both olanzapine and clozapine, but not risperidone have relatively high affinities for the 5-HT 2C receptor. On the other hand, olanzapine has higher affinity for ␣ 1 -than ␣ 2 -adrenergic receptors whereas clozapine and risperidone share high affinities for both ␣ 1 -and ␣ 2 -adrenergic receptors (Bymaster et al. 1996) . It is therefore plausible that the maximal augmentation with olanzapine plus fluoxetine treatment is mediated by either 5-HT 2C or ␣ 1 -adrenergic receptors. However, haloperidol has relatively high affinity for ␣ 1 -adrenergic receptors (Bymaster et al. 1996) and did not augment catecholamine release.
Our study is the first to investigate changes on monoamine release in PFC using an antipsychotic plus SSRI regimen, however, previous studies applying receptor specific drugs have provided useful clues to the mechanism that we are seeking. For example, the 5-HT 2C receptor agonist Ro 60-0175 markedly suppressed dialysate levels of [DA] (Millan et al. 1998) . These data suggest that 5-HT 2C receptors exert a tonic, inhibitory influence on frontocortical dopaminergic and adrenergic transmission, possibly via their excitatory effects on GABAergic interneurons (Millan et al. 1998; Pessia et al. 1994) . When in combination with fluoxetine, the 5-HT 2C antagonistic property of olanzapine could facilitate the persistent and robust effect on [DA] ex and [NE] ex release in PFC. It is also possible that other receptors than just 5-HT 2C and ␣ 1 -adrenergic receptors are involved in the augmentation, since olanzapine has such a rich binding profile. A subtle combination of different affinities for a number of receptors could result in the unique, persistent and robust effects produced by the olanzapine and fluoxetine combination treatment.
From a different point of view, some unique features of the pharmacology of fluoxetine could also contribute to the superior effects of the olanzapine and fluoxetine combination treatment. Although both fluoxetine and sertraline presumably exert antidepressant effects by increasing brain 5-HT levels as a result of blocking serotonin reuptake (Heym and Koe 1988; Koe et al. 1983; Wong et al. 1983 by fluoxetine were also seen in hypothalamus, another brain region of relevance in depression, as reported by previous studies Fuller 1992, 1997) . The olanzapine and fluoxetine combination treatment greatly increased both [DA] ex and [NE] ex , even at 4 hours after the initial drug treatment. In contrast, when combined with olanzapine, sertraline only significantly increased [DA] ex more than either drug alone and the effect on [DA] ex was much smaller than the combination of olanzapine and fluoxetine. This in part suggests that the increase of [5-HT] ex may be relevant to the augmentation of [DA] ex in the combination treatment, whereas the increase of [NE] involves an additional mechanism. Interestingly, fluoxetine also has a relatively high affinity for 5-HT 2C receptors (Wong et al. 1991 ), a feature not shared by other SSRIs including sertraline. In clonal cell lines transfected with 5-HT 2C receptors and in rat choroid plexus, fluoxetine behaved as an antagonist (Palvimaki et al. 1996) . All these data are consistent with our above postulation of an involvement of 5-HT 2C receptors in augmentation of [DA] ex and [NE] ex in PFC by the olanzapine and fluoxetine combination treatment.
Our current observations have provided a neurochemical hypothesis for the antidepressant effect in TRD patients observed in the recent olanzapine plus fluoxetine clinical trial (Tohen et al. 1999) . Olanzapine has been shown to produce significantly greater improvement in mood than haloperidol among patients with comorbid mood disorders and schizophrenia (Tollefson et al. 1997 ) and also appeared effective in psychotic depression (Rothschild et al. 1999) . Fluoxetine, on the other hand, has been proved to be efficacious in the treatment of depression due to increased [5-HT] ex (for review see Wong et al. 1995) . When olanzapine was combined with fluoxetine, the combination therapy not only produced marked improvement over either single treatment alone for TRD, but also resulted in a rapid onset of action (Tohen et al. 1999) . A deficiency in brain monoamine systems including that of 5-HT, DA, or NE have long been hypothesized for the pathogenesis of depression, and drugs that enhance 5-HT, DA or NE transmission in brain have been proven to have antidepressant effects (Maes and Meltzer 1995; Schatzberg and Schildkraut 1995; Willner 1995) . The brain region of interest in this study, PFC, plays a pivotal role in mood, arousal, and working memory, as well as integrating sensory input. Furthermore, its malfunction is suggested in the cognitive and emotional defects in affective and psychiatric disorders, such as depression and schizophrenia (Berman and Weinberger 1990; Goldman-Rakic 1996; Weinberger and Berman 1996) . Neuroanatomically, the PFC receives rich innervation from 5-HT, DA, and NE pathways originating from cell bodies in the dorsal raphe nucleus (DRN), ventral tegmental area (VTA), and locus coeruleus (LC), respectively. By complex and reciprocal modulations via auto-or hetero-receptors such as DA D 2 /D 3 , 5-HT 1A, 1B, 2A, 2C , and ␣ 1 -, ␣ 2 -adrenergic receptors, the PFC could also modulate the function of temporolimbic cortical and subcortical brain regions involved in mood and affect as well (Maes and Meltzer 1995; Schatzberg and Schildkraut 1995; Willner 1995) . Therefore, the persistent, robust increase of extracellular levels of DA, NE as well as similar increases of 5-HT in PFC produced by the combination treatment with olanzapine and fluoxetine provides a compelling mechanism for the clinical efficacy of the combination therapy in human TRD trials. In addition, therapy of TRD may require a robust increase of two or more of the monoamines and, thus, the combination therapy may have an additive and more powerful therapeutic effect compared to therapy involving an increase of only one neurotransmitter alone.
